Emerging reverse transcriptase inhibitors for HIV-1 infection.

about

Influence of Phosphatidylinositol-3-Kinase/Protein Kinase B-Mammalian Target of Rapamycin Signaling Pathway on the Neuropathic Pain Complicated by Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV Infection

P2860

Q58800269-1196D944-5E61-491A-AB55-4DA6BC860A65

P2860

Emerging reverse transcriptase inhibitors for HIV-1 infection.

Item

http://www.wikidata.org/entity/Q53686168

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Emerging reverse transcriptase inhibitors for HIV-1 infection.

@en

Emerging reverse transcriptase inhibitors for HIV-1 infection.

@nl

type

Item

label

Emerging reverse transcriptase inhibitors for HIV-1 infection.

@en

Emerging reverse transcriptase inhibitors for HIV-1 infection.

@nl

prefLabel

Emerging reverse transcriptase inhibitors for HIV-1 infection.

@en

Emerging reverse transcriptase inhibitors for HIV-1 infection.

@nl

P1476

Emerging reverse transcriptase inhibitors for HIV-1 infection.

@en

P2093

Carl J Fichtenbaum

http://www.w3.org/2001/XMLSchema#string

Mohammad A Rai

http://www.w3.org/2001/XMLSchema#string

Sam Pannek

http://www.w3.org/2001/XMLSchema#string

P2860

K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism

The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic

Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids

The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance

Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors

Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses

Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant

Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date

A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase

Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada

P304

1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14728214.2018.1474202

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2018-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29737220

http://www.w3.org/2001/XMLSchema#string

P932

6158299

http://www.w3.org/2001/XMLSchema#string

Emerging reverse transcriptase inhibitors for HIV-1 infection.

about

P2860

P2860

Emerging reverse transcriptase inhibitors for HIV-1 infection.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P577

P698

P932